Novartis Pharma AG inked a potential $900 million deal to gain exclusive global rights to a preclinical radioligand therapy (RLT) from Boomray Pharmaceuticals Co. Ltd., as the Swiss big pharma staves off increasing competition around Lutathera (lutetium [Lu 177] oxodotreotide).